The Elephant in the Room: Does Blend a Tumumab Really Improve Survival?

In the GMO data, there's a great graph of MRD rates over time. And they do increase as you get through, you know, course two or three months into therapy. That's when you start to see the plateau. So I think seeing how patients do long itudinally MRD response is a very reasonable way to kind of manage these patients in the real world, which this replicates. Yeah. We've talked about how there's a lot of drop off, but we haven't really talked about the elephant in the room. There was a protocol amendment. Should we talk about that? Probably should. Who wants to take a stab at it? You seem very passionate about